## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.8% below STRENGTH zone (4.0-10.0%); PEG 6.29 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($377.22)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Morgan Stanley initiates Waters Corp stock coverage with Equalweight rating**
- Source: Investing.com | 20251202T101700 | Neutral | Relevance: 100%
- Morgan Stanley initiated coverage on Waters Corp. (NYSE:WAT) with an Equalweight rating and a price target of $423.00, citing the company's strong financial performance and recurring business model. Despite its operational strengths and growth in new segments, concerns were raised regarding the acquisition of Becton Dickinson’s Biosciences and Diagnostics businesses, which could introduce "nearer-term uncertainty" and integration challenges. The investment bank noted that while the standalone business is favorable, these challenges could limit near-term visibility, aligning with analyst revisions and a high P/E ratio for Waters.

**2. Morgan Stanley initiates Waters Corp stock coverage with Equalweight rating**
- Source: Investing.com | 20251203T091023 | Neutral | Relevance: 100%
- Morgan Stanley initiated coverage on Waters Corp. (NYSE:WAT) with an Equalweight rating and a $423.00 price target, highlighting the company's strong financial performance and recurring business model. Despite positive operational efficiency and expansion into high-growth areas, concerns exist regarding the proposed acquisition of Becton Dickinson’s Biosciences and Diagnostics businesses due to potential integration challenges and "nearer-term uncertainty." This caution aligns with analysts' downward revisions for upcoming earnings and the stock's premium valuation, even as Waters reported strong Q3 2025 results.

**3. Waters Corporation $WAT Stock Holdings Raised by Korea Investment CORP**
- Source: MarketBeat | 20251203T071307 | Somewhat-Bullish | Relevance: 100%
- Korea Investment CORP significantly increased its stake in Waters Corporation ($WAT) by 43.2% in Q2, bringing their total holdings to 28,518 shares valued at $9.95 million. Other major institutions like AllianceBernstein and Wellington also boosted their positions, contributing to institutional investors owning approximately 94.01% of the company. Analysts maintain a "Moderate Buy" rating for Waters, with a consensus target price of $381.57.

**4. Morgan Stanley initiates Waters Corp stock coverage with Equalweight rating By Investing.com**
- Source: Investing.com South Africa | 20251202T171800 | Neutral | Relevance: 100%
- Morgan Stanley initiated coverage on Waters Corp. (NYSE:WAT) with an Equalweight rating and a price target of $423.00, citing its strong financial performance and recurring business model. Despite concerns about the integration of recent acquisitions, the company has shown revenue growth and expanding into high-growth areas. Waters Corporation also reported strong Q3 2025 financial results, exceeding analyst expectations for EPS and revenue.

**5. Morgan Stanley initiates Waters Corp stock coverage with Equalweight rating By Investing.com**
- Source: Investing.com Nigeria | 20251202T161800 | Neutral | Relevance: 100%
- Morgan Stanley has initiated coverage on Waters Corp. (NYSE:WAT) with an Equalweight rating and a price target of $423.00, acknowledging the company's strong financial performance and recurring business model. Despite its operational efficiency and expansion into high-growth areas, concerns exist regarding the integration challenges and "nearer-term uncertainty" following its announced acquisition of Becton Dickinson’s Biosciences and Diagnostics businesses. The stock currently trades at a high P/E ratio, and analysts have revised earnings downwards for the upcoming period.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |
| 2025-11-05 | TD Cowen | $390 | $345 | +13% |
| 2025-11-05 | Wells Fargo | $385 | $315 | +22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |
| 2025-11-05 | TD Cowen | main | Hold |
| 2025-11-05 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.3% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 6.3x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 6.29 signals overvaluation risk, limited margin of safety. Forward P/E 27.8x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Analyst sentiment positive (2 raises, avg +18%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.0B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.29 |
| Forward P/E | 27.8 |
| Current P/E | 30.3 |
| YoY Growth | 9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 7.1% to 0.8% (-6.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.2pp (needs >4.0% for momentum thesis). MRS_5 (-1.3%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.57), momentum weakening. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.78% (CS: 59) | Neutral |
| RSI_14 | 65.1 | Neutral |
| MACD Histogram | -0.57 | Bearish |
| vs SMA20 | 1.027x | Above |
| vs SMA50 | 1.124x | Above |
| vs SMA200 | 1.174x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $397.62
- **Stop Loss:** $377.22 (5.1% risk)
- **Target:** $418.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 46
- **Position Value:** $18,290.52
- **Portfolio %:** 18.29%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*